药品注册申请号:016619
申请类型:NDA (新药申请)
申请人:RISING
申请人全名:RISING PHARMA HOLDINGS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 SUBLIMAZE PRESERVATIVE FREE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Yes Yes AP 1968/02/19 Approved Prior to Jan 1, 1982 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/12/15 SUPPL-54(补充) Approval Labeling STANDARD
2022/08/08 SUPPL-45(补充) Tentative Approval Manufacturing (CMC) N/A
2022/04/12 SUPPL-52(补充) Approval Labeling STANDARD
2019/10/07 SUPPL-43(补充) Approval Labeling STANDARD
2019/01/24 SUPPL-39(补充) Approval Labeling STANDARD
2016/12/16 SUPPL-38(补充) Approval Labeling STANDARD
2016/05/18 SUPPL-37(补充) Approval Manufacturing (CMC) PRIORITY
2013/07/03 SUPPL-34(补充) Approval Labeling STANDARD
2003/10/17 SUPPL-32(补充) Approval Labeling STANDARD
1996/04/26 SUPPL-31(补充) Approval Labeling STANDARD
1995/02/22 SUPPL-30(补充) Approval Manufacturing (CMC) PRIORITY
1993/12/23 SUPPL-29(补充) Approval Labeling
1993/12/23 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1993/12/23 SUPPL-27(补充) Approval Manufacturing (CMC) PRIORITY
1993/12/23 SUPPL-26(补充) Approval Manufacturing (CMC) PRIORITY
1992/12/07 SUPPL-24(补充) Approval Manufacturing (CMC) PRIORITY
1992/10/28 SUPPL-25(补充) Approval Manufacturing (CMC) PRIORITY
1991/11/25 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1990/07/05 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1989/09/14 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1987/01/27 SUPPL-20(补充) Approval Labeling
1986/09/05 SUPPL-19(补充) Approval Labeling
1986/09/05 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1985/09/10 SUPPL-17(补充) Approval Labeling
1983/09/07 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1983/03/11 SUPPL-13(补充) Approval Manufacturing (CMC) PRIORITY
1982/07/07 SUPPL-12(补充) Approval Labeling
1982/07/07 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1981/02/24 SUPPL-10(补充) Approval Labeling
1981/02/24 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1980/05/23 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1976/11/08 SUPPL-4(补充) Approval Labeling
1968/02/19 ORIG-1(原始申请) Approval Type 3 - New Dosage Form PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:FENTANYL CITRATE 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 0.05MG BASE/ML 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
016619 001 NDA SUBLIMAZE PRESERVATIVE FREE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription Yes Yes AP Approved Prior to Jan 1, 1982 RISING
019101 001 NDA FENTANYL CITRATE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription Yes Yes AP 1984/07/11 HIKMA
019115 001 NDA FENTANYL CITRATE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription No No AP 1985/01/12 HOSPIRA
072786 001 ANDA FENTANYL CITRATE PRESERVATIVE FREE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription No No AP 1991/09/24 HOSPIRA
210762 001 ANDA FENTANYL CITRATE PRESERVATIVE FREE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription No No AP 2019/05/03 FRESENIUS KABI USA
212086 001 ANDA FENTANYL CITRATE FENTANYL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription No No AP 2020/09/01 FRESENIUS KABI USA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database